Anixa Biosciences (NASDAQ:ANIX) Shares Down 0.4%

Anixa Biosciences, Inc. (NASDAQ:ANIX)’s stock price traded down 0.4% on Wednesday . The stock traded as low as $2.26 and last traded at $2.26. 12,534 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 118,743 shares. The stock had previously closed at $2.27.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on shares of Anixa Biosciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, June 10th.

Anixa Biosciences Price Performance

The stock’s 50-day moving average price is $2.65 and its 200-day moving average price is $3.40.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Tuesday, June 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. On average, sell-side analysts forecast that Anixa Biosciences, Inc. will post -0.43 EPS for the current year.

Insiders Place Their Bets

In related news, Director Lewis H. Titterton, Jr. purchased 15,009 shares of the company’s stock in a transaction that occurred on Tuesday, April 9th. The stock was acquired at an average price of $3.28 per share, with a total value of $49,229.52. Following the completion of the purchase, the director now directly owns 838,037 shares in the company, valued at $2,748,761.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 10,738 shares of Anixa Biosciences stock in a transaction on Friday, June 7th. The shares were purchased at an average price of $2.52 per share, with a total value of $27,059.76. Following the acquisition, the director now owns 848,775 shares in the company, valued at approximately $2,138,913. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lewis H. Titterton, Jr. purchased 15,009 shares of the stock in a transaction dated Tuesday, April 9th. The shares were acquired at an average cost of $3.28 per share, with a total value of $49,229.52. Following the acquisition, the director now directly owns 838,037 shares in the company, valued at approximately $2,748,761.36. The disclosure for this purchase can be found here. Insiders have purchased a total of 57,732 shares of company stock worth $153,491 in the last 90 days. Company insiders own 22.60% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC grew its position in Anixa Biosciences by 274.6% during the 4th quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock worth $2,110,000 after acquiring an additional 39,820 shares during the last quarter. Simplicity Wealth LLC acquired a new stake in shares of Anixa Biosciences during the first quarter valued at about $44,000. Staley Capital Advisers Inc. acquired a new stake in shares of Anixa Biosciences during the first quarter valued at about $31,000. Finally, Virtu Financial LLC grew its holdings in shares of Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock worth $50,000 after purchasing an additional 5,183 shares during the last quarter. 29.13% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.